Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose 3.6 ...
Eli Lilly said sales of its blockbuster diabetes treatment, Trulicity, rose 20% from last year to $1.23 billion, but overall revenues missed analysts' forecasts. Eli Lilly & Co. (LLY) posted ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Eli Lilly lifts 2024 sales view by $2 billion on weight-loss drug demand Updated / Tuesday, 30 Apr ... The drugmaker also raised its annual profit forecast by $1.30 per share to $13.50 to $14 per ...
LLY has been on a tear, with their stock price hitting all-time highs recently and closing the week at around $820. However, ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook 1h ... Eli Lilly raised 2024 revenue guidance to $42.4-$43.6 billion from $40.4-$41.6 billion, driven by tremendous sales growth for ...
NEW YORK — Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses ...